All In Biotech

Drug Trial Radar · NCT01818492

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis

Last checked: Nov 20, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

45

Actual

Start

Jul 2013

Primary completion

Jan 2019

Study completion Jan 2019

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
Seventh Framework Programme
First posted
Mar 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the current standard of care. Administration will be on top of a glucocorticosteroid, which is usually part of the current recommended treatment.

Conditions

  • Primary Haemophagocytic Lymphohistiocytosis

Interventions

  • NI-0501Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Second LineTime frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)
  2. Overall Response Rate (ORR) All TreatedTime frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)
  3. Overall Response Rate (ORR) Follow-on Analysis Set:Time frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)
  4. Overall Response Rate (ORR) at End of Treatment in Study NI-0501-04 (EOT 04) Follow-on Analysis Set: All TreatedTime frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology

    Wilmington, Delaware

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Dana-Farber Cancer Institute (DFCI)

    Boston, Massachusetts

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital - Division of Immunobiology - Department of Pediatrics

    Cincinnati, Ohio

  • Texas Children's Cancer Center

    Houston, Texas

  • Primary Children's Hospital

    Salt Lake City, Utah

  • University Children's Hospital

    Münster, Germany

  • Azienda Ospedaliero Universitaria Meyer

    Florence, Italy

  • Istituto Giannina Gaslini

    Genoa, Italy

  • Azienda Ospedaliera San Gerardo

    Monza, Italy

  • Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica

    Padua, Italy

  • Ospedale Pediatrico Bambino Gesu'

    Roma, Italy

  • Ospedale Donna Bambino - U.O.C. Oncoematologia Pediatrica

    Verona, Italy

  • Hospital Sant Joan de Déu

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Niño Jesús

    Madrid, Spain

  • Karolinska University Hospital

    Stockholm, Sweden

  • Great Ormond Street Hospital - Department of Haematology

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.